IRONWOOD PHARMACEUTICALS, INC. Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest
IRONWOOD PHARMACEUTICALS, INC. (IRWD) had Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest of -$161.84 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest
us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest · last filed 2026-08-06
- 2026-06-30: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -$161.84M.
- 2026-03-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -$217.14M.
- 2025-12-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -$261.83M.
- 2025-09-30: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -$264.16M.
| Period end | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest |
|---|---|
| 2026-06-30 | -$161.84M 10-Q · filed 2026-08-06 |
| 2026-03-31 | -$217.14M 10-Q · filed 2026-08-06 |
| 2025-12-31 | -$261.83M 10-Q · filed 2026-08-06 |
| 2025-09-30 | -$264.16M 10-Q · filed 2025-11-10 |
| 2025-06-30 | -$308.16M 10-Q · filed 2026-08-06 |
| 2025-03-31 | -$334.05M 10-Q · filed 2026-08-06 |
| 2024-12-31 | -$301.33M 10-Q · filed 2026-08-06 |
| 2024-09-30 | -$311.33M 10-Q · filed 2025-11-10 |
| 2024-06-30 | -$321.73M 10-Q · filed 2025-11-10 |
| 2024-03-31 | -$330.52M 10-Q · filed 2025-11-10 |
| 2023-12-31 | -$346.30M 10-Q · filed 2025-11-10 |
| 2023-09-30 | -$325.68M 10-Q · filed 2024-11-07 |
| 2023-06-30 | -$346.78M 10-Q · filed 2024-11-07 |
| 2023-03-31 | $706.85M 10-Q · filed 2024-11-07 |
| 2022-12-31 | $652.38M 10-K · filed 2025-03-31 |
| 2022-09-30 | $591.06M 10-Q · filed 2023-11-09 |
| 2022-06-30 | $532.88M 10-Q · filed 2023-11-09 |
| 2022-03-31 | $517.78M 10-Q · filed 2023-11-09 |
| 2021-12-31 | $605.91M 10-K · filed 2025-03-31 |
| 2021-09-30 | $579.94M 10-Q · filed 2022-11-03 |
| 2021-06-30 | $511.76M 10-Q · filed 2022-11-03 |
| 2021-03-31 | $110.19M 10-Q · filed 2022-11-03 |
| 2020-12-31 | $62.64M 10-K · filed 2024-02-16 |
| 2019-12-31 | -$93.25M 10-K · filed 2023-02-16 |
| 2012-12-31 | $144.05M 10-K · filed 2013-02-21 |
| 2011-12-31 | $109.86M 10-K · filed 2013-02-21 |
| 2011-09-30 | $112.93M 10-Q · filed 2011-11-09 |
| 2011-06-30 | $130.12M 10-Q · filed 2011-08-12 |
| 2010-12-31 | $159.55M 10-K · filed 2013-02-21 |
| 2009-12-31 | -$298.34M 10-K · filed 2013-02-21 |
| 2008-12-31 | -$230.41M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |